M&R Capital Management Inc. cut its stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 10.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 18,692 shares of the healthcare product maker’s stock after selling 2,116 shares during the quarter. M&R Capital Management Inc.’s holdings in Abbott Laboratories were worth $2,131,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors have also bought and sold shares of ABT. Hanson & Doremus Investment Management raised its holdings in shares of Abbott Laboratories by 0.8% during the 2nd quarter. Hanson & Doremus Investment Management now owns 11,165 shares of the healthcare product maker’s stock valued at $1,160,000 after buying an additional 92 shares in the last quarter. Encompass More Asset Management raised its position in Abbott Laboratories by 3.3% in the 2nd quarter. Encompass More Asset Management now owns 3,002 shares of the healthcare product maker’s stock worth $312,000 after purchasing an additional 96 shares during the period. Wynn Capital LLC lifted its stake in Abbott Laboratories by 2.9% in the first quarter. Wynn Capital LLC now owns 3,427 shares of the healthcare product maker’s stock worth $390,000 after purchasing an additional 98 shares during the last quarter. NORTHSTAR ASSET MANAGEMENT Co LLC grew its stake in shares of Abbott Laboratories by 1.9% during the first quarter. NORTHSTAR ASSET MANAGEMENT Co LLC now owns 5,396 shares of the healthcare product maker’s stock valued at $613,000 after buying an additional 100 shares during the last quarter. Finally, Hummer Financial Advisory Services Inc increased its holdings in shares of Abbott Laboratories by 1.2% in the first quarter. Hummer Financial Advisory Services Inc now owns 8,290 shares of the healthcare product maker’s stock worth $942,000 after buying an additional 100 shares during the period. Hedge funds and other institutional investors own 75.18% of the company’s stock.
Insider Buying and Selling
In other Abbott Laboratories news, CEO Robert B. Ford sold 141,679 shares of the business’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $116.41, for a total value of $16,492,852.39. Following the sale, the chief executive officer now directly owns 220,059 shares of the company’s stock, valued at $25,617,068.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.10% of the stock is currently owned by company insiders.
Analysts Set New Price Targets
Abbott Laboratories Trading Up 0.1 %
NYSE ABT opened at $113.64 on Thursday. The firm has a market capitalization of $197.69 billion, a PE ratio of 35.40, a P/E/G ratio of 2.86 and a beta of 0.72. The stock’s 50 day moving average is $112.10 and its 200 day moving average is $108.19. Abbott Laboratories has a twelve month low of $89.67 and a twelve month high of $121.64. The company has a quick ratio of 1.18, a current ratio of 1.68 and a debt-to-equity ratio of 0.33.
Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its earnings results on Thursday, July 18th. The healthcare product maker reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.04. Abbott Laboratories had a net margin of 13.65% and a return on equity of 20.18%. The firm had revenue of $10.38 billion for the quarter, compared to analysts’ expectations of $10.37 billion. During the same quarter in the previous year, the business posted $1.08 EPS. The company’s quarterly revenue was up 4.0% on a year-over-year basis. Research analysts forecast that Abbott Laboratories will post 4.66 earnings per share for the current fiscal year.
Abbott Laboratories Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, November 15th. Stockholders of record on Tuesday, October 15th will be given a $0.55 dividend. The ex-dividend date is Tuesday, October 15th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 1.94%. Abbott Laboratories’s dividend payout ratio is currently 68.54%.
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
See Also
- Five stocks we like better than Abbott Laboratories
- Most Volatile Stocks, What Investors Need to Know
- Dine Brands’ Transformation Plan: A Recipe for Recovery?
- Basic Materials Stocks Investing
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.